> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Janssen Scraps Hep C Therapy Due to Saturated Market
- URL: https://www.fdaweb.com/janssen-scraps-hep-c-therapy-due-to-saturated-market/
- Published: 2017-09-11T12:00:00.000Z
- Updated: 2026-09-14T22:48:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139588

Janssen Sciences has decided to discontinue development of its investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct-acting antivirals — AL-335, odalasvir and simeprevir. While ongoing Phase 2 studies with JNJ-4178 will be completed as planned, the decision to abandon the program is based on “increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C,” the company says.

Janssen previously co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus. In partnership with Medivir AB, Janssen subsequently developed and launched a second generation protease inhibitor, Olysio (simeprevir).